Walgreens study links pharmacy communication to patient adherence
A recent Walgreens study points to a connection between pharmacy communication and patient adherence. Read More »
A recent Walgreens study points to a connection between pharmacy communication and patient adherence. Read More »
Amgen's results from its Phase 3 Tower study evaluating Blincyto’s efficacy have been published in the New England Journal of Medicine. Read More »
AbbVie shared the successful results of its Phase IIb clinical trial on elagolix on patients suffering from heavy menstrual bleeding due to fibroids last week. Read More »
McKesson, the platinum sponsor of CBI’s Formulary, Co-Pay and Access Summit is presenting a new approach to patient-centric behavioral coaching with the overall goal of improving adherence despite affordability and other barriers. Read More »
Biologics Inc., which is owned by McKesson Specialty Health, has been chosen as the exclusive specialty pharmacy provider for BAVENCIO (avelumab). Read More »
The U.S. Food and Drug Administration (FDA) has granted Bristol-Myers Squibb Co. a priority review for the company’s Opdivo Biologics License Application. Read More »
Walgreens and Prime Therapeutics LLC merge to offer specialty pharmacy and mail services Read More »
AbbVie's supplemental new drug application for ibrutinib, a product for treating chronic graft vs. host disease (cGVHD) after failure of one or more lines of systemic therapy, has received FDA approval. Read More »
Health care supply distributor McKesson Corp. of San Francisco has completed its acquisition of CoverMyMeds LLC, an Ohio-based source of electronic authorization technology for medical providers and pharmacists. Read More »
Change Healthcare recently announced the unveiling of InterQual 2017, the company’s flagship clinical decision support solution. Read More »
Amgen and UCB recently announced that their phase 2 study for Evenity (romosozumab) showed positive fourth-year results for efficacy and safety as a second course of treatment for postmenopausal women with osteoporosis. Read More »
Bristol-Myers Squibb Co. and Incyte Corp. have agreed to advance their clinical development program. Read More »
Amgen recently announced that the company submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for Xgeva (denosumab). The company also seeks approval from the European Medicines Agency (EMA). Read More »
The European Medicines Agency has accepted a Marketing Authorization Application for brexpiprazole, and its review is anticipated in the second quarter of 2018. Read More »
AbbVie has received approval from the U.S. Food and Drug Administration to include moderate to severe fingernail psoriasis data in the Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. Read More »
Amgen's esults from its Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO has been published in the Journal of Clinical Oncology. Read More »
AbbVie has joined three other pharmaceutical companies in the Oncology Research Information Exchange Network Avatar Research Program. Read More »
Walgreens recently designated over 50 of its nationwide pharmacy locations as cancer specialty centers outfitted with highly trained staff in breast, prostate, colorectal, lung and blood cancer directives with specialized curricula. Read More »
Based on 27,564 patient cardiovascular outcomes study, Amgen has established that maximally reducing low-density lipoprotein cholesterol levels with Repatha leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations. Read More »
Amgen recently announced that the European Commission (EC) granted the company authorization to bring to market Amgevita in all available indications. Read More »